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1052-11 Serum Uric Acid Level Is an independent Predictor of 
Restenosis After Successful Percutaneous 
Transluminal Coronary Stent Implantation 
Kazuaki Kumagai, Masatake Fukunami, Tsuyoshi Shimonagata. Takahisa Yamada, Akio 
Hirata. Mitsutoshi Asai, BMakino, Hidetaka Kioka, Noritake Hoki, Osaka 
Prefectural General Hospital, Osaka, Japan. 
Background: Inflammatory activities have been shown to be associated with an 
increased risk for ischemic coronary events after percutaneous transluminal coronary 
stent implantation (PTCS). Serum uric acid (UA), reflecting oxidative radical activity 
through xanthine oxidase, might be also a potent marker for chronic inflammation. How- 
ever, it is not elucidated whether elevated UA levels would be related to target lesion res- 
tenosis (TLR) following PTCS. Therefore, we studied whether UA level might be one of 
predictors of TLR. This study included 217 consecutive patients following successful 
PTCS without renal dysfunction and without serum UA-lowering drugs. Results: During 
the follow-up period of 2 years, TLR occurred in 46 patients (21%). In patients with TLR, 
serum UA level just before PTCS were significantly higher than in patients without TLR 
(6.5i1.5 vs. 5.6+1.5mg/dl. p=O.oM)3). Patients with UA of >7.0mg/dl had a significantly 
higher TLR rate (43%) at 2 years after PTCS than that (28%) in patients with UA of 
7.0mg/dl or less (p<O.OOOl , Kaplan-Meier analysis and log-rank test). Univariate analysis 
revealed that UA level (p=O.o003), sex (p-0.09), the diameter of stent (p=O.O19), serum 
C-reactive protein level (p=O.O93) and DM (p&044) were predictive of TLR, but that 
age, smoking, hypertension, hyperlipidemia, acute coronary syndrome, prior myocardial 
infarction or medications were not. Furthermore, Cox hazard model showed that UA level 
(hazard ratio; t 34, 95% Cl; 1.09-1.64, p=O.O05), serum C-reactive protein level (hazard 
ratio; 1.62, 95% Cl; 1 .Ol-2.59, p=O.O44) and the diameter of stents (hazard ratio: 0.35, 
95%CI; 0.14-0.66, p&025) were independent predictors of TLR. Conclusion: This 
study indicates that elevated serum uric acid level just before PTCS would be a most 
powerful independent predictor of TLR following successful PTCS. 
1052-12 Does Stent Design Affect Platelet Activation? Results of 
the Platelet Activation in Stenting (PAST) Study 
PaulA.GurbeL Kevin P. Callahan, Michele J. Buczkowski, Victor L. Serebruany. Sinai 
Hospital, Baltimore, Maryland. 
BACKGROUND: Platelet activation induced by coronary artery stenting affects clinical 
outcomes and may be related to stent design. However, little is known about how platelet 
activation may be altered by the specific design of a stent. METHODS: Patients (n=53) 
were randomly assigned to stenting with a closed-cell (NIR. Boston Scientific) or open- 
cell (TETRA, Guidant) stent. Patients were treated with aspirin and were loaded with 300 
mg clopidogrel in the cath lab and received 75 mg daily thereafter. All stents were 
deployed at > 12 atm. GPllblllla inhibitors were not used. Platelet aggregation (5~ mol 
ADP and lpglml collagen): and flow cytometry (mean fluorescence intensity (MFI)) to 
multiple platelet receptors and platelet-leukocyte aggregates (CD 151 + 14) were serially 
determined at baseline, and at 2 hours (2h), 24 hours (24h). 5 days (5d) and 30 days 
(30d) post procedure.RESULTS: Stenting was successful in all patients. Markers of 
platelet activation were less following NIR implantation: 30d ADP aggregation (%) (32.3+ 
6.1 YS 44.5+ 16.9, p=.O2); 24h CD31 (136f 46 VS. ll& 46, p=.O4); 24h (104? 45 YS 91* 
31 p=.O46) and 30 d CD 151 (99f 33 vs 61f 32, p=.O3); 24h (93f 40 vs. 77i 24, p=.O16) 
and 30d CD 151+14 (64k 35 vs. 72f 31, p=.O45); 30d PAC-1 (66+ 41 vs. 72* 30, 
pz.025); and 2h (22f 13 vs 16f 5, p=.O45) and 24 h CD 107a (24i 12 vs. 17 f 4, p=.O3). 
CONCLUSIONS: In this randomized prospective trial, platelet activation; indicated by 
enhanced aggregation and expression of multiple receptors; was greater during the 30 
days following implantation of an open-versus a closed-cell stent. Stent-dependent plate- 
let activation may be relevant to the propensity for subacute thrombosis and restenosis 
associated with a particular stent design. 
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1053-l Early and Sustalned Survival Benefit Associated With 
Statln Therapy at the Time of Percutaneous Coronary 
intervention 
e, Deepak L. Bhatt. Derek P. Chew, Martin J. Quinn. David J. Moliterno, 
Eric J. Topol, Stephen G. Ellis, The Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Long-term administration of statin therapy has been shown to reduce 
major coronary events and cardiac mortality in clinical trials. Beyond lipid lowering, 
statins favorably affect platelet adhesion, thrombosis, endothelial function, inflammation, 
and plaque stability, which may potentially improve outcome after PCI. Therefore, we 
hypothesized that statin therapy has an early beneficial effect in patients undergoing PCI. 
Methods: Each year from 1993 through 1999, we prospectively collected data and fol- 
lowed our first 1.000 patients undergoing PCI. Baseline, procedural, and 6-month data of 
statin-treated and non-statin-treated patients were compared. Propensity score and mul- 
tivariate survival analysis were used to adjust for heterogeneity between the 2 groups. 
Results: Of 6,647 patients with completed follow-up, 23.5% were treated with statin at 
the time of the procedure. Statin therapy was associated with a 60% lower mortality at 30 
days (1.0% YS 2.5%. p = 0.0007) and a 37% reduction at 6 months (3.1% vs 4.9%, p = 
0.003). After adjusting for the propensity to receive statin therapy prior to the procedure 
and for other confounders, statin therapy remained an independent predictor for survival 
at 6 months following PCI (HR 0.66. 95% C.I. 0.46-0.93, p = 0.017). The mortality benefit 
was independent of p&procedural MI, recurrent MI. and target vessel revascularization. 
Conclusion: Statin therapy among PCI patients was associated with a significant mortal- 
ity lowering at early and intermediate term follow-up. The mechanism of survival benefit 
of statin beyond lipid-lowering needs further elucidation. 
1053-2 A Blinded Multicenter Dose Escalation Phase Ila Study 
of the Factor VIMIssue Factor Inhlbltor Recombinant 
Nematode Anticoagulant Protein c2 In Patients 
Undergoing Elective Percutaneous Coronary 
Intervention 
Arno H. Moon_& N. R. Bijsterveld, H. R. Biiller, M. H. Prins, W. E. Rote, G. P. Vlasuk, R. J. 
Peters, Academic Medical Center, Amsterdam, The Netherlands, Cowas International, 
San Diego, California. 
fntroductlon: A multicenter, randomized, double-blind, placebo controlled, dose escala- 
tion study in patients undergoing elective percutaneous coronary intervention (PCI) eval- 
uated the safety of recombinant Nematode Anticoagulant Protein c2 (rNAPcP), a potent 
inhibitor of the factor VII&issue factor (FVlla/TF) complex. 
Methods: Patients received either placebo or rNAPc2 from one of 4 dose groups as a 
single SC administration 2-6 hours before PCI, as well as aspirin and IV unfractionated 
heparin (activated clotting time > 250 set). The primaty endpoints were femoral com- 
pression time (FCT) after sheath removal, and incidence of major and minor bleeding. 
Secondary endpoints included the plasma concentration of prothrombin activation frag- 
ment 1+2 (Flc2) over time. 
Result% 
rNAPc2 n FCTB F1+2 (nmol/L)b Bleeding n(%) 
(pS/kg) (min) 
Bh? 24 he 36 he Minor Major 
placebo 30 10 (10-27) 1.2 (0.6) 1 .l (0.6) 1.4 (0.9) 2 (7) 0 (0) 
3.5 23 10 (10-16) 0.7 (0.3)” 0.7 (0.2)“’ 0.9 (0.3)’ 1 (4) 0 (0) 
5.0 24 10 (10-15) 0.6 (0.3)’ 0.6 (0.3)” 1.0 (0.5) 1 (4) 3 (13) 
7.5 27 10 (10-70) 0.7 (0.4)” 0.7 (0.2)“’ 0.7 (0.2)” 3 (11) t (4) 
10.0 26 16 (10-50)” 0.6 (0.7) 0.7 (0.2)” 0.7 (0.2)” 6 (31) 0 (0) 
amedian (range) bmean (SD); ‘after PCI, dafter rNAPc2; 
P-value: rNAPc2 vs placebo: ‘co.05 “<O.Ol “‘<O.OOl 
FCT and minor bleeding, but not major bleeding, demonstrated a dose-dependent 
increase. All three patients that developed major bleeding in the 5.0 pgikg dose group 
also received a glycoprotein Ilb/llla receptor antagonist. rNAPc2, regardless of dose, pro- 
duced a prolonged, significant suppression of thrombin generation as measured by 
plasma F1+2 extending over 24 hours after the single SC administration. 
Conclusions: These results suggest that FVlla/TF inhibition with rNAPc2 is a safe and 
potentially effective strategy for prevention of thrombotic complications in patients under- 
going coronary interventions. This study supports further investigation of rNAPc2 in 
patients suffering from acute coronary syndromes. 
1053-3 The REPLACE 1 Trial: A Pilot Study of Bivalirudin 
Versus Heparin During Percutaneous Coronary 
Intervention Wlth Stentlng and GP IlMlla Blockade 
A. Michael I incnff, John A. Bittl, Neal S. Kleiman, Dean J. Kereiakes, Robert A. 
Harrington, Ian J. Sarembock, J. Daniel Jackman, Sameer Mehta, Elizabeth F. Maierson, 
Derek P. Chew, Eric J. Topol, for the REPLACE Investigators. Cleveland Clinic 
Foundation, Cleveland, Ohio. 
Background: The direct thrombin inhibitor bivalirudin (previously “Hirulog”) has been 
associated with improved efficacy and less hemotiage than heparin during balloon 
angioplasty, but has not yet been widely tested with stenting or GP llblllla antagonists. 
Methods: In a pilot study, 1056 pts undergoing elective or urgent coronary intervention 
(PCI) at 77 sites in the US were randomized in a central, open-label fashion to receive 
heparin (60-70 U/kg initial bolus) or bivalirudin (0.75 mg/kg bolus, 1.75 mglkg-hr infusion 
during PCI). All pts received aspirin, and pretreatment with clopidogrel was encouraged. 
GP Ilb/llla inhibitor use was per operator preference. Endpoints were death, MI, repeat 
revascularization, or major bleeding by hospital discharge or 46 hours. 
Results: Stents were used in 65% of pts; 72% received a GP IlWllla inhibitor. Activated 
cloning times were significantly higher among pts randomized to bivalirudin than hepadn 
prior to device deployment (371 +I- 102 set vs. 304 +I- 69 set, pcO.001) and at proce- 
dure end (334 +/- 63 set vs. 267 +/- 56 sac, p-zO.001). individual endpoints and the “Tri- 
ple”(death. MI, revasc) and “Quadruple’ composites (death, MI. revasc, major bleeding) 
are detailed in the Table (all p = NS). 
Death (%) 
Ml (%) 
Repeat Revascularization (%) 
Major Bleeding (%) 
“Triple” Composite (%) 
“Quadruple” Composite (%) 
Heparin (n = 524) Bivalirudin (n = 532) 
0.6 0 
5.2 4.9 
2.3 1.5 
2.7 2.1 
6.9 5.6 
6.6 7.1 
